

[Adalimumab](#)

Essential medicine status

Section:

[29. Medicines for diseases of joints](#) [29.3. Medicines for juvenile joint diseases](#)

ATC codes: [L04AB04](#)

EMLc

Indication

Juvenile idiopathic arthritis ICD11 code: [FA24.Z](#)

INN

Adalimumab

Medicine type

Biological agent

List type

Complementary

Additional notes

EML: certolizumab pegol, etanercept, golimumab and infliximab are alternatives, including quality-assured biosimilars.

EMLc: etanercept and infliximab are alternatives, including quality-assured biosimilars.

Formulations

Parenteral > General injections > SC: 40 mg per 0.8 mL ; 40 mg per 0.4 mL ; 10 mg per 0.2 mL (EMLc) ; 20 mg per 0.4 mL (EMLc)

EML status history

First added in 2019 ([TRS 1021](#))

Changed in 2023 ([TRS 1049](#))

Sex

All

Age

Also recommended for children

Therapeutic alternatives

[certolizumab pegol](#) (ATC codes: [L04AB05](#))

[etanercept](#) (ATC codes: [L04AB01](#))

[golimumab](#) (ATC codes: [L04AB06](#))

[infliximab](#) (ATC codes: [L04AB02](#))

Patent information

Main patents have expired but secondary patents might remain active in some jurisdictions. For more information on specific patents and license status for developing countries visit www.MedsPal.org

Read more [about patents](#).

Tags

Biological

Wikipedia

[Adalimumab](#)

DrugBank

[Adalimumab](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations on the EMLc, the Expert Committee recommended the addition of new strength formulations of adalimumab (injection 10 mg/0.2 mL and 20 mg/0.4 mL) to the EMLc. Listing of adalimumab for the indication of juvenile idiopathic arthritis was transferred from Section 8.1 (Immunomodulators for non-malignant disease) to Section 29.3 (Juvenile joint diseases).